BeyondSpring Inc. Logo

BeyondSpring Inc.

Develops innovative immuno-oncology cancer therapies, including a 'pipeline in a drug' asset.

BYSI | US

Overview

Corporate Details

ISIN(s):
KYG108301006
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, 7932 FLORHAM PARK
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BeyondSpring Inc. is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. The company is committed to improving clinical outcomes and raising the standard of care for cancer patients. Its lead asset, Plinabulin, is being developed as a 'pipeline in a drug' for multiple cancer indications. BeyondSpring is also an equity owner of SEED Therapeutics, a company specializing in Targeted Protein Degradation (TPD) technology to discover and develop novel 'molecular glues' for breakthrough therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BeyondSpring Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BeyondSpring Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BeyondSpring Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan 4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan 6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan 4978
RESEARCH FRONTIERS INC Logo
Develops and licenses smart glass tech for instant light, UV, and heat control.
United States of America REFR
Resolute Holdings Management, Inc. Logo
Asset management firm acquiring and operationally enhancing companies for long-term growth.
United States of America RHLD
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan 4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan 9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom RGP

Talk to a Data Expert

Have a question? We'll get back to you promptly.